ClinicalTrials.gg

Program

JZP047

A development code.

Its studies are led by Jazz Pharmaceuticals.

Furthest: phase 1, since Jan 21, 20261 company-led study, 1 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jazz Pharmaceuticals11 open or runningphase 1since Jan 21, 2026Jan 21, 2026Nov 30, 2026phase 1 · NCT07377539

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 21, 2026First study: phase 1 study in Healthy ParticipantsFirst studyNCT07377539 · 86 enrolled · United States
  2. Oct 23, 2026Primary completion moved from 2026-07-05 to 2026-11-30Date moved laterphase 1 · +5 months · NCT07377539

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07377539

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07377539Healthy Participants · United States1Active, not recruitingNov 30, 202686

How it is read

Names in the registry

  • “JZP047”, 1 entry

Codes read as this program: JZP047.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.